Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies

J Clin Oncol. 2024 Mar 10;42(8):973-974. doi: 10.1200/JCO.23.02259. Epub 2024 Jan 30.

Authors

David J Stewart¹, Tim Ramsay¹, Vishal Navani¹, Geoffrey Liu¹, Di Maria Jiang¹, Gerald Batist¹

Affiliation

¹ David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada.

PMID: 38290085
DOI: 10.1200/JCO.23.02259

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents* / therapeutic use
Disease-Free Survival
Humans
Neoplasms* / drug therapy
Progression-Free Survival

Substances

Antineoplastic Agents